Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2014

View Archived Issues

Synergism observed with dabrafenib and trametinib combination in melanoma

Discovery of BRD-3444, a new antimalarial by diversity-oriented synthesis strategy

Novartis cancels launch in Japan of Rasilamlo combination tablets LD and HD

Phase III trial of entinostat begins in advanced breast cancer

Pfizer reports data from phase III study of Xalkori in NSCLC

Med BioGene confirms CLIA approval for GeneFx Lung

Rosetta Genomics collaborates with Clalit Health Services' Rabin Medical Center

Myriad Genetics and Tesaro form HRD companion diagnostic collaboration

Cellceutix initiates trial of Prurisol for psoriasis

PI3K signaling pathway implicated in uterine carcinosarcoma

DMC recommends that COMET-1 study continue to completion

Mologen initiates lung cancer trial of MGN-1703 in Belgium

NIH funds new research consortium for Ebola virus

New PI3K inhibitors disclosed by Roche and Genentech

Janssen R&D Ireland prepares novel compounds for HBV infection

Researchers at Gruenenthal disclose novel calcium channel blockers

Canadian group presents new antibacterial agents

e-Therapeutics recommences patient recruitment in phase I U.K. trial of ETS-2101

LEO-43204 demonstrates efficacy against actinic keratosis in a first-in-human clinical trial

CXD-101 and companion diagnostic studied in new phase I trial

Daiichi Sankyo announces East Asian subgroup analyses from edoxaban trials

Onconova presents in vivo data for ON-146040

Genocea reports updated results from phase I/IIa HSV-2 study of GEN-003

GlaxoSmithKline receives Japanese approval of its nucleic acid analogue for HBV

Albiglutide approved in Europe for type 2 diabetes

FDA accepts NDA for migraine candidate AVP-825

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...